Skip to main content

The Interventional Cardiology team at Nationwide Children’s Hospital in Columbus successfully implanted the reSept ASD Occluder in the first enrolled Ohio patient as part of the ASCENT ASD study.

ASCENT ASD is a research study authorized by the US FDA to assess the safety and efficacy of the reSept ASD occluder, to treat patients with significant ASDs. reSept is the first transcatheter septal occluder with a metal-free frame. Occluders currently available have a metal frame that remains in the patient’s heart for life.

“Decades ago, the closure of ASDs became minimally invasive with the first transcatheter occluder. The next advancement in ASD device technology is to make these devices bioresorbable so that a metal frame is not left behind. This allows transseptal interventions to be much easier later in life, if treatment for arrhythmia is needed,” said Dr. Aimee Armstrong, Director of Cardiac Catheterization and Interventional Therapies at Nationwide Children’s Hospital and Professor of Pediatrics at The Ohio State University College of Medicine.

An atrial septal defect is a hole in the wall between the top two chambers of the heart. ASDs are among the most common heart defects in children. They can be treated with a device through a minimally invasive procedure in most patients. Please follow the link for further information on ASDs.

In the US, the ASCENT ASD Study is currently enrolling patients in over 20 centers.